Mechanisms underlying bone loss associated with gut inflammation by Ke, Ke et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2019 





Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
 International Journal of 
Molecular Sciences
Review
Mechanisms Underlying Bone Loss Associated with
Gut Inflammation
Ke Ke 1, Manoj Arra 1 and Yousef Abu-Amer 1,2,*
1 Department of Orthopaedic Surgery and Cell Biology and Physiology, Washington University School of
Medicine, St. Louis, MI 63110, USA; ke.ke@wustl.edu (K.K.); arram@wustl.edu (M.A.)
2 Shriners Hospital for Children, St. Louis, MI 63110, USA
* Correspondence: abuamery@wustl.edu; Tel.: +1-314-362-0335
Received: 29 October 2019; Accepted: 10 December 2019; Published: 15 December 2019


Abstract: Patients with gastrointestinal diseases frequently suffer from skeletal abnormality,
characterized by reduced bone mineral density, increased fracture risk, and/or joint inflammation.
This pathological process is characterized by altered immune cell activity and elevated inflammatory
cytokines in the bone marrow microenvironment due to disrupted gut immune response.
Gastrointestinal disease is recognized as an immune malfunction driven by multiple factors, including
cytokines and signaling molecules. However, the mechanism by which intestinal inflammation
magnified by gut-residing actors stimulates bone loss remains to be elucidated. In this article, we
discuss the main risk factors potentially contributing to intestinal disease-associated bone loss, and
summarize current animal models, illustrating gut-bone axis to bridge the gap between intestinal
inflammation and skeletal disease.
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1. Introduction
The intestinal immune system is primarily involved in controlling and limiting mucosal immune
responses to enteric and ingested bacterial antigens, through the actions of gut-associated lymphoid
tissue (GALT) [1]. GALT is also involved in mounting appropriate immune responses to pathogenic
bacteria in order to protect the body. However, inappropriate GALT activity results in a variety of
unnecessary or disrupted immune activity which could manifest as functional disorders within or
beyond the gastrointestinal (GI) tract [2–4]. Inflammatory bowel disease (IBD) is one such systemic,
bowel-centric condition with chronic immune activation and inflammation within the GI tract that
to this date remains poorly understood. Ulcerative colitis (UC) and Crohn’s disease (CD) are two
distinct forms of IBD, both characterized by a multifactorial, incompletely known etiology involving
genetic components, environmental factors, and altered gut microbiota (GM) [5]. The extra-intestinal
manifestation in IBD patients involves development of disease in other organs, including the joints,
skin, or eyes [6], that can lead to significant co-morbidities and loss of quality of life.
Patients with GI disease, especially IBD, are at a significantly higher risk of developing skeletal
disease, such as osteoporosis (OP) (17–41% of patients) or osteopenia (22–77% of patients), and other
enteropathic arthropathies [7–10]. OP is a systemic skeletal disease characterized by significantly
reduced bone mass/mineral density (BMD) and deterioration of bone microarchitecture [11]. Cases
of OP are classified as primary or secondary. Primary OP is the most common and prevalent form,
including juvenile, postmenopausal and senile OP. The causes of secondary OP are vast and attributed
to underlying diseases, including hematological diseases, GI disease, vitamin deficiency, solid organ
transplantation, and chronic medication [12]. The main therapies for treating OP target bone remodeling
involve either inhibiting the bone resorbing osteoclasts (OCs) or promoting the activity of bone forming
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osteoblasts (OBs) [13]. Although bone alterations in IBD patients is considered to be one of the most
prevalent forms of secondary OP, the underlying pathological mechanisms in IBD patients are complex
and still relatively unknown. In addition to low bone mass, GI disease is also characterized by its
inflammatory joint disease with features similar to psoriasis, rheumatoid arthritis, and connective
tissue diseases [14]. Certain extra-intestinal manifestation on joints is related to disease activity and
specific location in the gut [10]. Overall, bone and joint conditions cause severe morbidity and even
mortality in patients with gut diseases such as IBD, requiring a greater understanding of the connection
between these two systems. In this review, we discuss and summarize the current known knowledge
underlying the mechanism of gut inflammation-mediated skeletal dysfunction in humans.
2. Main Risk Factors of Bone Deterioration in Patients with GI Disease
Skeletal disorders present in GI disease such as IBD are thought to result from a complex interplay
of environmental and host factors.
2.1. Genetic Factors
A complex genetic background could be a common feature in the etiology of gut inflammation
and bone loss. Several genomic studies including polymorphic analysis have been investigated to
show some of the susceptibility loci overlap for both diseases, including but not limited to Interleukin
(IL)-1β, TNFSF11 (Receptor Activator of Nuclear Factor Kappa-B Ligand, RANKL), TNFRSF11B
(Osteoprotegerin, OPG), IL-6, and Vitamin-D receptor (VDR).
2.1.1. IL-1β
IL-1β is a well characterized pro-inflammatory cytokine implicated in various inflammatory
disorders. The IL-1β locus has been implicated in genetic susceptibility to IBD [15,16]. IL-1β is a
well-known player in bone loss in RA patients that promotes osteoclastogenesis [17]. Furthermore,
Nemetz et al. showed an increased risk of bone loss in IBD patients with IL-1B polymorphism (IL1B-511,
rs16944) associated with hyper secretion of IL-1β [18]. Treatment of IBD patients diagnosed with
systemic onset juvenile idiopathic arthritis with IL-1β antagonists showed well-controlled systemic
juvenile idiopathic arthritis (sJIA) symptoms at time of diagnosis of IBD [19].
2.1.2. RANKL/OPG
RANKL and OPG are two competing molecules critical for the process of bone remodeling.
RANKL promotes osteoclastogenesis by binding to RANK and activating downstream signal cascades
such as the nuclear factor kappa-B (NF-κB) pathway. OPG acts as a decoy for RANKL and can
competitively interfere with its binding to RANK, thus, creating a fine tuned balance between bone
resorption and formation. Altered RANKL/OPG system has been described to be associated with a
lower BMD found in IBD patients. Moschen et al. paradoxically showed elevated plasma OPG in IBD
patients as well as high levels of OPG released from the inflamed colonic mucosa [20]. However, a
negative correlation between OPG plasma levels and spine and femoral neck BMD were found in
osteoporotic IBD patients. Although plasma levels of soluble RANKL is not changed, an increased
numbers of RANKL+ cells were noted in the lamina muscularis of IBD patients [20]. It is possible
that in these patients, OPG levels are elevated as a compensatory mechanism in order to counteract
the effects of pro-inflammatory cytokines. In addition, it is still unclear how local versus systemic
effects of RANKL and OPG differ. Taranta et al. [21] showed an increased RANKL/OPG ratio and
lower expression of the OC inhibitory cytokines IL-12 and IL-18 [22] in the sera of untreated celiac
patients, pointing to potential peripheral blood mononuclear cell-derived impact on osteoclastogenesis.
Interestingly, a recent polymorphism study found that the c.-223T allele of the OPG-encoding gene
TNFRS11B was twice more frequent in CD patients than among controls, though the average level
of OPG is not significantly different from controls. In UC patients, OPG levels were significantly
lower, suggesting that low OPG levels may be associated with bone loss in UC, but not correlated
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with c.-223C>T (rs2073617) polymorphism in the TNFRS11B gene [23]. Furthermore, RANKL has
gut-intrinsic functions by acting as a critical factor for the development of M cells [24], which are
involved in antigen sampling and modulation of the gut immune response. This gut-produced RANKL
may escape into systemic circulation and also have impacts on the cells of the skeletal system. Therefore,
a further understanding of the roles of local and systemic RANKL/OPG on bone loss in the context of
IBD is required.
2.1.3. IL-6
IL-6 is a cytokine that has both pro-inflammatory and anti-inflammatory properties, though it
is widely accepted as a pro-osteoclastogenic factor. IL-6 expression is driven by various pathways,
including the NF-κB and MAPK pathways, among others. The literature concerning genetic variations
of IL-6 expression in predisposing OP in IBD patients appears contradictory. Genetic variation analysis
identified IL-6 gene as being associated with increased risk of bone loss in IBD patients [25], especially
with CD [26]. However, a previous study from the Schulte group showed a genetic response to
stress in IBD patients could not support IL-6 as a major predictor for the degree of bone disease.
This coincides with several contradictory findings regarding the role of IL-6 in modulating osteoclasts
and osteoblasts in bone remodeling. The role of IL-6 in gut-bone axis requires further study to resolve
these conflicting findings.
2.1.4. Vitamin D Receptor (VDR)
Vitamin D is hydrophobic nutrient critical for various body processes and skeletal health. Vitamin
D can be produced endogenously in the body through the function of melanocytes or can be obtained
nutritionally. Vitamin D is modified to its active form, and its binding to the intracellular VDR
activates its downstream functions. A recent study from Szymczak-Tomczak et al. [27] revealed
that although IBD patients did not display differences in serum 25(OH)D in comparison to control
subjects, a protective effect of the VDR gene TaqI (rs731236, c.1057T>C) allele on BMD was seen in IBD
patients and controls. Particularly, a higher femoral neck bone mass was found to be associated with tt
genotypes of VDR gene in UC patients [27]. Another study based on North Indian postmenopausal
women showed the frequency of TT genotypes was highly expressed in osteoporotic women compared
to controls with normal BMD [28]. The role of VDR in the modulation of bone health is under intense
debate [29,30] due to a number of cohort effects (age, district, genetic background, disease activity, etc.).
2.2. Microbiota
The microbiome of an individual consists of more than 1000 microbial species including bacteria
and single-celled eukaryote. Homeostatically, the gut microbiota (GM) provides colonization resistance
and regulates immune balance bidirectionally within the epithelial barrier and tissue environment,
to protect the host from invading pathogens [31]. Perturbed balance in microbial composition has
been postulated to be associated with compromised immunity within the gut, and an increased
susceptibility to the development of enteropathic arthropathies, such as spondyloarthropathy and
psoriatic arthritis [32–34]. A recent cross-sectional study displayed an increased abundance in the
Clostridiaceae family of bacteria was shared by patients with IBD-associated arthropathy and RA,
potentially due to the effects of bowel surgery history [35]. Fecal microbiota study reveals patients with
spondyloarthritis (SpA) had a significant abundance of Ruminococcus gnavus, compared with both RA
and healthy controls, correlated with a history of IBD in patients [36]. This emerging evidence suggests
a potentially common microbial link for inflammatory arthritis and gut inflammation. However, it
remains unknown whether enteropathic arthropathies are secondary to inflammation induced by
gut dysbiosis.
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2.3. Vitamin D Homeostasis
Among IBD patients, reduced BMD or osteopenia is associated with a lack of nutrient intake
and defective nutrient utilization, mainly as a result of vitamin deficiency, insufficient calcium uptake
and ultimately malabsorption due to destruction of intestinal villi. Surveys on dietary habits and
nutrient intake showed lower bone density in malnourished IBD patients [37] especially when
undergoing a flare. The gut, bone, and kidney are the major players regulating calcium homeostasis.
The calcium homeostatic cycle is regulated systemically and locally by vitamin D and parathyroid
hormone (PTH) [37]. Vitamin D is absorbed primarily in the duodenum of the small intestine
through dietary consumption, as well as de novo synthesis in the skin by UV irradiation. Activity
of 1, 25-dihydroxyvitamin D (Vitamin D3), the biologically active form of vitamin D, is mainly
functionally mediated by the vitamin D receptor (VDR) [38]. Vitamin D increases calcium absorption
in the gut, prevents calcium loss in the nephrons of the kidney, and inhibits bone resorption overall.
Systemic vitamin D level is reported to be positively correlated with colonic VDR expression in healthy
subjects [39]. However, IBD patients showed a reduced expression of epithelial VDR in inflamed
large bowel [40,41], indicating VDR may work as an important gatekeeper maintaining mucosal
barrier function. GWAS analysis of the gut microbiota identified a significant association of bacterial
abundance and VDR loci [42]. Although recent studies on correlation between VDR and its relationship
with IBD-associated bone loss are still in debate [27–30], targeting local expression of VDR, particularly
in the epithelial barrier, might be a potential solution to manipulate vitamin D homeostasis in both IBD
patients and OP subjects. Del Pinto et al. performed meta-analysis to display that UC patients possess
a greater association with vitamin D deficiency than patients with CD [43]. Several studies showed
pediatric and adolescent populations with IBD possess greater vitamin D deficiency than healthy
subjects [43–46]. The trend towards decreased vitamin D-VDR activity likely partially contributes
to the poor bone health in pediatric IBD patients [47,48], although contrasting results have been
shown [49]. High risks for bone disease in IBD patients are partly due to impaired intestinal calcium
absorption [37]. Since vitamin D/VDR works as crucial players in maintaining gut immune function,
especially through regulating gut barrier potential [50], increased production of proinflammatory
cytokines due to vitamin D deficiency may also synergistically increase prevalence of both intestinal
immune response and malabsorption.
2.4. Medication
Anti-inflammatory and immunosuppressive drugs are commonly prescribed to IBD patients for
induction and maintenance of remission during treatment. Corticosteroids, such as glucocorticoids,
are the standard treatment for IBD for their rapid effect on reducing symptoms [51]. However, long
term and/or high dose consumption of systemic corticosteroids results in rapid bone loss, accompanied
with lower BMD and increased risk of fracture [52]. Excessive glucocorticoids consumption disrupts
bone remodeling through increasing OB apoptosis, elevating RANKL/OPG levels, and stimulating
osteoclastogenesis [53]. Additionally, glucocorticosteroid treatment significantly increases serum
fibroblast growth factor-23 level in pediatric patients with idiopathic nephrotic syndrome [54] and
receiving kidney transplant [55]. Elevated systemic fibroblast growth factor-23 level was also found to
be associated with low BMD in childhood IBD [56], suggesting importance of management of steroids
treatment in IBD patients. Prospective clinical trials by introduction of alternative immunosuppressive,
such as azathioprine, and anti-tumor necrosis factor (TNF) agents, including infliximab, showed a
superior therapeutic effect in IBD patients; however, the association of BMD, drug therapy, and the
prevalence of disease activity need to be analyzed further [9].
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3. Animal Models of Gut Inflammation-Induced Bone Loss
Recent studies characterizing bone loss in animal models of intestinal inflammation, demonstrated
that gut residing immune cells as well as inflammatory mediators such as inflammatory cytokines,
signaling proteins and endocrine factors, contributed to GI-disease-induced bone destruction. To better
understand the interaction between bone loss and immune system in gut disease, various animal
models of gut disease have been utilized. Generally, animal models of gut inflammation are mainly
established using genetic modification, gut-residing microbiome modification, immune cell transfer
(transferring T effector cells into immune-deficient mice), or chemical induction (e.g., TNBS, DSS).
These models can then be used to study the effect on the skeletal system. A list of selected animal
models indicating skeletal abnormalities seen in gut inflammation is summarized in Table 1.
Table 1. Animal models indicating linkage between gut-bone axis signaling.
Models Based on Genetic Modification
Animal Strains GI Phenotype Skeletal Phenotype Systemic and OtherOrgan Phenotype Reference















1,25(OH)2D3 and PTH ↑
[62–65]




↑; BV/TV, Ct.Th., Tb.N.,
Tb.Th. ↓; mineralization







bone mass, Tb.Th. and
Tb.N. ↓
bone formation ↓
%Th17-TNFα+ in BM ↑
serum OCN ↓










































A20myel-KO mice less stable microbiota
severe polyarthritis
macrophage NF-κB





lymph nodes Th17 ↑
[78,79]











cytokines and CTX ↑ [80–82]
FXR−/−mice barrier dysfunctionapoptotic goblet cells






trabecular bone mass ↓ N/A [86,87]
Models Based on Dysbiosis-Associated Gut Inflammation
Animal Strains GI Phenotype Skeletal Phenotype Systemic and OtherOrgan Phenotype Reference
GF mice
serotonin ↑
CD4+ T cells ↓
TNFα ↓
BV/TV, Tb.N. and BFR ↑;
Tb.Sp. and OC.N. ↓
BM-CD4+T cells, Th17,
TNFα and IL-6 ↓
BM-OC precursor ↓OC
fusion ↓
serum OCN, CTX, Ca2+,













IGF-1 and RANKL in BM ↑





Models Based on Chemical Induction
Animal Strains GI Phenotype Skeletal Phenotype Systemic and OtherOrgan Phenotype Reference
TNBS crypt loss, cellularity,and edema
BV/TV, BFR and osteoid
surface ↓ OC.S ↑
% of TNFα+, IL-6+,
RANKL+, and OPG+
osteocytes ↓





colon TNF, IFNγ, IL-17,
IL-1β ↑
cortical bone fraction ↓
BV/TV and Tb.Th ↓
serum OCN and RANKL
↓




urinal Ca2+ excretion ↑
renal TRPV5 and Klotho
↓
[70,92]
DSS mucosal inflammationand ulceration
BMD, Tb.Th., MAR, and
Ct.BMD ↓
OB.Ar ↓ OC.Ar ↑
Growth plate height and
cartilage gene ↓





DSS colonic length ↓ Alveolar bone loss ↑ Liver cystine ↓ [94]
DSS
lymphocyte aggregates
↑; colon TNFα, IFNγ,




growth plate thickness and
ColX ↓
BFR and osteoblast surface
(OB.S) ↓; TNFα ↑
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Table 1. Cont.
Adoptive Transfer of Effector Immune Cells to Immunodeficient Mice








BV/TV, Conn.D, Tb.N, and
Tb.Th. ↓















SAA and WBC ↑
RBC, haemoglobin, and
haematocrit ↓










Abbreviation: BFR, bone formation rate; BV/TV, Bone volume/Total volume; BMD, bone mineral density; BM,
bone marrow; BW, body weight; Conn.D, connective density; Ct.Ar/Tt.Ar, cortical bone fraction; MAR, mineral
apposition rate; Oc.S, OC surface; OB, osteoblast; OC, osteoclast; RBC, red blood cell; SAA, serum amyloid; SCFA,
short chain fatty acid; TJ protein, Tight junction proteins; Tb. Sp., trabecular spacing; Tb.Th., trabecular thickness;
tDPD, deoxypyridinoline; WBC, white blood cell; N/A, not applicable; n.s., no significant difference. ↑ indicates
increase, ↓ indicates decrease.
3.1. Models Based on Genetic Modification
3.1.1. HLA-B27 Transgenic (B27-Tg) Rats
Human Leukocyte Antigen (HLA)-B27 is a major histocompatibility complex class I molecule and
is highly expressed on antigen-presenting cells for pathogen recognition. HLA-B27 is notably genetic
associated with Ankylosing spondylitis, a class of immune-mediated arthritis termed ‘spondyloarthritis’
(SpA) [98]. The prevalence of HLA-B27 in SpA/IBD populations is still questionable [33], but HLA-B27
was found to be positively associated with inflammatory back disorders [99], and asymmetrical,
nonerosive peripheral arthritis (namely oligoarticular) in IBD patients [100–103]. HLA-B27 transgenic
(B27-Tg) rats develop a multisystemic inflammatory disease that display two important inflammatory
features, IBD and peripheral arthritis resembling human spondyloarthritis [57]. B27-Tg rats are
susceptible to both alveolar bone loss and long bone osteopenia with decreased biomechanical strength,
increased bone resorption, increased RANKL/OPG mRNA ratio in bone tissue [58], and enhanced
osteoclastogenesis [59]. However, this model displayed normal serum level of bone formation markers,
such as OCN [60] and PINP [58], which indicates that inflammation-associated bone loss in B27-Tg
rats is mainly driven by increased bone resorption. Previous studies revealed HLA-B27-associated
gut and joint inflammation is prevented when transgenic rats were in a germ-free environment [104].
Recent studies from Ansalone et al. [61] demonstrated that B27-Tg rats have enhanced number of
bone erosive circulating monocytes, which are highly dependent upon microbiota-regulated intestinal
inflammation. These findings highlight the participation of intestinal microbiome in the pathologic
relation between HLA-B27-associated gut, bone loss, and joint inflammation.
3.1.2. VDR−/−Mice
VDR null mice were generated to understand the role of Vitamin D3 in the gut-bone axis.
In addition to bone and intestine, VDR is widely expressed in many other tissues including endocrine
tissues, skin, kidney, bone marrow, and lymphoid tissues. 1,25(OH)2D3 and VDR, and together
with other active co-regulatory proteins results in maintenance of calcium homeostasis by increasing
calcium absorption from the intestine and preventing bone resorption. Deficiency of VDR in mice
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caused rickets, osteomalacia, hypocalcemia, and hyperparathyroidism, and those symptoms were
prevented when a high calcium (2%) containing diet were fed in VDR null mice, which indicates
that VDR deficiency induced skeletal disorder are principally as a result of failed intestinal calcium
absorption [62,63]. Further studies from Xue et al. [64], using transgenic expression of VDR in the
intestine of VDR-knockout mice, showed that calcium homeostasis was directly restored, and that
intestinal VDR is essential for controlling bone formation. IEC-specific VDR knockout (Vdr(∆IEpC))
mice exhibit abnormal body size and colon structure [66], and significantly-reduced skeletal calcium
levels that maintain normal levels of ionized calcium in serum. Additionally, increased compensatory
1,25(OH)2D3 levels in Vdr(∆IEpC) mice did not rescue increased bone turnover and suppressed bone
matrix mineralization, leading to osteopenia [67]. Most recent studies on the roles of VDR expressed in
bone cells revealed that VDR in OBs, but not in OCs, negatively regulate bone mass, since ablation of
VDR in OBs results in reduced bone resorption with a decreased expression of RANKL in OBs [105,106].
Although the role of VDR and vitamin D on the progression of IBD is unclear, VDR and vitamin D may
be important for proper bone remodeling and formation of high quality bone in the setting of disease.
3.1.3. IL-10 Deficiency
IL-10 is a well-known anti-inflammatory cytokine, and decreased IL-10 levels contribute to
pathological development in both IBD and inflammatory bone disease. In the study from Drezner-Pollak
et al., IL-10−/−mice spontaneously develop colitis and exhibit decreased bone mass due to decreased
bone formation, without affecting bone resorption [68]. The primary defect in bone formation in
IL-10−/−mice was evidenced by decreased bone formation rate, serum OCN level, and mineralized
nodule number in bone marrow stromal cell cultures. A following study from Ciucci et al. compared
bone from IL-10−/− mice with colitis to IL-10−/− mice without colitis by histomorphometry [69].
IL-10−/− mice with colitis developed a significant bone defect with reduced trabecular thickness,
trabecular number, and bone surface density [69]. Those findings show that osteopenia and OP
found in IL-10−/− mice is primarily due to colitis-associated intestinal inflammation, but not IL-10
deficiency. However, it has been shown that IL-10 itself inhibits bone resorption by decreasing
osteoclastogenesis [107,108]. Additional work is required to reconcile these mechanistic differences.
3.1.4. IL-2 Deficiency
IL-2, a cytokine predominantly secreted by activated T cells, is critical for the development and
peripheral expansion of CD4+CD25+ regulatory T cells, promoting self-tolerance by suppressing T cell
responses in vivo [109,110]. IL-2−/−mice spontaneously develop a systemic autoimmune inflammation
characterized by colitis, hepatitis, pneumonia, hemolytic anemia, and osteopenia [71,72]. Ashcroft et
al. showed that IL-2 deficient mice developed colitis and pronounced osteopenia with reduced bone
formation and increased OC number, caused by elevated level of RANKL in both serum and bone
marrow mononuclear cells. IL-2 deficient mice display heavily inflamed large bowel with significantly
higher systemic RANKL level at 7 weeks. The abundance of RANKL may also benefit survival and
activity of intestinal dendritic cells by activating pathogenic T cells [72,111]. Transfer of CD3+ T cells
from IL-2−/−mice into lymphocyte-deficient C57BL/6-Rag1−/−mice, resulted in lower femoral BMD,
trabecular volume, and significantly higher number of OCs. This work suggests activated T cells, due
to IL-2 deficiency, may contribute to induction of bone loss in the setting of colitis by inducing OC
formation. It emphasizes the importance of IL-2 as a therapeutic target for bone defects associated
with intestinal inflammation.
3.1.5. Tnf ∆ARE Mice
Tumor necrosis factor (TNF) is a main factor linking the pathology of gut-bone axis. This was
demonstrated by TNF transgenic mouse model (Tnf ∆ARE mice), generated by deleting TNF AU-rich
elements (ARE) responsible for destabilizing activity on the TNF message. These mice spontaneously
develop chronic inflammatory polyarthritis at weeks 5–6 and Crohn’s-like IBD at week 6 [73]. Moreover,
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these mice showed enhanced circulating TNF levels and profound capacity of macrophages and T cells
to produce TNF. This model is effective for studying severe systemic inflammatory diseases as seen in
clinical human patients, since most patients have systemic inflammation that is not isolated to a single
organ system. However, the systemic nature of this model makes it difficult to understand the specific
effect of gut inflammation on other regions of the body.
3.1.6. gp130∆STAT/∆STAT and gp130Y757F/Y757F Mice
The proinflammatory cytokine IL-6 and its receptor gp130 are essential for the pathogenic
development of both intestinal and bone disease, such as RA. Genetic manipulation of the IL-6/leukemia
inhibitory factor (LIF) cytokine axis through sustained activation of gp130 in mice (gp130-KI
mice/gp130∆STAT/∆STAT), causes severe joint disease with features representative of RA, and interestingly,
GI ulceration [74]. Those mice showed a severe chronic synovitis, degraded articular cartilage
associated with disrupted chondrocyte differentiation, but normal trabecular bone volume (BV/TV)
and turnover [75]. gp130∆STAT/∆STAT mice display sustained gp130-dependent signal transducer and
activator of transcription (STAT) signaling cascades due to impaired STAT-mediated induction of
suppressor of cytokine signaling-1 (SOCS-1), which normally functions to limit gp130 signaling [112].
Dysregulation of STAT1 and/or STAT3 activity is associated with human hematological and intestinal
disease [113], such as gastric cancer [114]. Unlike gp130∆STAT/∆STAT mice, BV/TV was reduced in gp130
receptor mutant mice (gp130Y757F/Y757F) due to highly activated bone turnover [75]. The work from
this model, combined with evidence that IL-6 levels are elevated in IBD patients, suggests a role for
gut-induced IL-6 expression as a mediator of bone quality.
3.1.7. Hematopoietic Cell-Specific STAT3-KO Mice (STAT3-CFF; Tie2Cre+-Stat3fl/fl)
Signal transducer and activator of transcription 3 (STAT3) is a transcriptional mediator responsible
for the expression of many inflammatory cytokines, including IL-6, IL-10, and G-CSF [115], exerting
its role in a cell-specific way [116]. Mice with hematopoietic cell-specific disruption of STAT3
gene (STAT3-CFF) generate an osteoporotic phenotype with hyperproliferated myeloid lineages and
increased number of OC precursors, indicating existence of higher osteoclastogenic factors in those
mutant mice [117]. Another study from Welte et al. showed STAT3-CFF mice displayed a CD-like
pathogenesis in both the small and large intestine, characterized with segmental inflammatory cell
infiltration, ulceration, and formation of granuloma [76]. An alternative study also documented
that STAT3-CFF mice have defective stem/progenitor cells with mitochondrial dysfunction, increased
reactive oxygen species (ROS) production, and a rapid aging-phenotype [77]. All these findings suggest
that STAT3 signaling pathway and its associated factors, such as ROS and mitochondrial function,
contribute to both inflammatory bowel and bone diseases. Work remains to be done on connecting
the two organs in this model and understanding how bowel-specific STAT3 signaling may affect
bone remodeling.
3.1.8. A20 (Tumor Necrosis Factor α-Induced Protein3; TNFAIP3) Deficiency
Nuclear factor-κB, a key nuclear transcriptional factor, is a central player in regulating expression
of a variety of genes encoding proinflammatory cytokines, adhesion molecules, chemokines, growth
factors, and inducible enzymes [118,119]. NF-κB itself is activated by many different stimuli ranging
from inflammatory cytokines to genotoxic stress. Pathogenesis in both IBD and inflammatory bone
disease is characterized by elevated inflammatory cytokines, many of which are regulated through
activation of NF-κB signaling. Dysregulation of NF-κB inhibitory pathways in mice can cause severe
systemic inflammation. One such model is characterized by reduced A20 (tumor necrosis factor
α-induced protein3; TNFAIP3) expression (A20-KO mice), which normally regulates NF-κB activation.
A20 deletion triggers severe inflammatory conditions in multiple organs, including livers, kidney,
intestines, joints, and bone marrow, and dies prematurely [120]. Studies on cell-specific A20 function,
by using conditional knockout mice, showed that A20 deficiency in myeloid cells (A20myel-KO)
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results in spontaneous development of severe destructive polyarthritis resembling RA [78]. Although
intestinal epithelial cell (IEC) specific A20 knockout mice, and A20myel-KO mice showed preserved
intestinal integrity, models combining IEC and myeloid A20 deletion display ileitis and severe colitis,
characterized by elevated inflammatory cytokine pool [79]. This work suggests that both an extracellular
source of inflammatory stimulation, combined with defective intestine-specific intracellular signaling,
may be required for the development of gut disease.
3.1.9. IKK2caIEC Mice
To further interrogate the role of NF-kB signaling in the gut-bone axis, our lab generated
an IEC-specific model of NF-κB overactivation. The findings from our studies using IEC-specific
constitutively activated IKK2 mice (IKK2caIEC) model highlight direct and crucial role of intestinal
NF-κB signaling in linking chronic gut inflammation with bone loss [80]. IKK2caIEC develop a
mild inflammation in small intestine [81]; however, with significantly elevated serum and epithelial
level of inflammatory cytokines. Importantly, IKK2caIEC mice recapitulate the majority of the
phenotypes observed in chemically (Dextran sulfate sodium/DSS) induced colitis, such as altered
gut-residing cells and elevated osteoclastogenic cytokines. Furthermore, moderate attenuation of
NF-κB signaling by using conditional deletion of one allele of IKK2 in IECs or pharmacological
inhibition of IKK2, partially attenuated circulating levels of inflammatory cytokines, such as IL-17, and
halted colitis-associated bone loss. This indicates that NF-κB signaling in intestinal cells is not only
critical for gut inflammation-mediated damage, but also extra-intestinal effects.
3.1.10. FXR−/−Mice
The farnesoid X receptor (FXR), a nuclear receptor for bile acids, is highly expressed in intestine
and liver and responsible for maintaining bile acid homeostasis. FXR displays various functions in
different organs, and the FXR antagonists have been developed for pre-clinical and clinical application
for management of liver and other metabolic disease [121]. FXR−/− mice display compromised
intestinal epithelial barrier due to increased bacterial invasion [122], increased colon cell proliferation
and apoptotic goblet cells, accompanied with upregulation of genes involved in cell cycle progression
and inflammation, such as cyclin D1 and IL-6 [83]. The changes in the intestinal microbiota during
metabolic dysfunction, such as obesity and alcoholic liver disease, have been shown to be associated
with FXR [123,124]. FXR deficiency leads to cell proliferation, inflammation, and tumorigenesis in
gut, and FXR can protect small intestine from bacterial invasion and colonization [125]. Cho et al.
demonstrated that FXR−/−mice display reduced bone formation rate as well as low trabecular bone
volume and reduced thickness [84]. Evaluation of FXR effect on bone cell differentiation showed
that mice with FXR deficiency had reduced OB differentiation [84], and enhanced OC generation [85].
Zheng et al. [85] assessed role of FXR in different pathological bone loss models (calvarial injection
of LPS, in vivo rosiglitazone treatment, ovariectomy (OVX) surgery, and unloading-induced bone
loss), and reported that deficiency of FXR accelerated bone loss in animal model of postmenopausal
OP and unloading-induced bone loss. Taken together, these findings strengthen both biological and
pathological function of FXR in bone loss and highlight a possible role of FXR in connecting intestinal
inflammation and its-related bone disease when FXR is downregulated. Further work has to be
performed to determine how intestinal inflammation may modulate FXR ligands to signal to the
skeletal system through cell specific deletion models.
3.1.11. Mdr2−/−Mice
Multi-drug resistance 2 (encoded by mdr2/Abcb4), known as a canalicular phospholipid flippase,
is responsible for transport of phospholipid into bile by increasing eﬄux of intracellular hydrophobic
drugs observed in multidrug resistance (MDR) [126,127]. The mdr2−/−mouse spontaneously develops
severe biliary fibrosis due to an accumulation of toxic bile acids, and is considered as a model of
primary sclerosing cholangitis (PSC) [128]. PSC is a cholestatic liver disease characterized by chronic
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inflammation and progressive destruction of the bile ducts. PSC displays remarkable associations
with IBD, dysbiosis and higher incidence of fracture risk [129,130]. Mdr2−/−mice display an altered
GM, intestinal barrier dysfunction, and activation of NLRP3 inflammasome within the gut–liver axis.
Interestingly, healthy control mice transferred with Mdr2−/−microbiota develop significant liver injury,
highlighting the key function of intestinal dysbiosis in the progression of liver disease [86]. Schmidt et
al. demonstrated decreased bone mass in PSC patients is associated with increased bone resorption, as
well as increased peripheral blood T helper (Th)17 cells. Experimental studies showed that Mdr2−/−
mice had a higher Th17 cell frequency in liver. Analysis of skeletal phenotype displayed that absence
of Mdr2 in mice resulted in osteopenia with reduced trabecular bone mass, and this phenotype was
prevented by the additional Il17af deficiency [87]. An increased Th17 response to microbial stimulation
was found in PMC patients with UC [131]. These findings point out that mdr2-regulated dysbiosis may
contribute to two major complications found in PSC patients: IBD and bone loss, potentially through
modulation of immune cell populations.
3.2. Models Based on Dysbiosis-Associated Gut Inflammation
The gut is an especially unique organ system due to the present of its vast microbiome that is
critical for healthy function but also pathophysiology. Dysbiosis is highly associated with GI disease,
characterized by imbalanced microbiota population as well as microbial metabolism. Therefore,
recent work using animal models to manipulate host microbiota offer a method to understand the
role of the microbiome in gut-related disease and associated bone loss. Animal studies to explore
dysbiosis-regulated bone loss were mainly performed by using germ-free (GF) animals and antibiotic
treatment [132].
3.2.1. Germ-Free (GF) Models
GF models are established by raising animals in sterile conditions, which result in a lack of
microbiota in those animals and an immature mucosal immune system [133]. This allows for
colonization with specific microbiota to determine the effect of individual bacterial species on physiology.
GF animals display enlarged ceca, reduced total mass of intestine and total surface of small intestine,
shorter crypts of small intestine, and decreased cellularity in lamina propria, compared to conventionally
raised animals (CONV-R) [134]. GF mice displayed increased trabecular bone mass due to compromised
osteoclastogenesis, compared with CONV-R mice. Colonization of young GF mice (3 weeks old) with
normal GM (for 4 weeks) normalized bone mass to a level similar to CONV-R mice [88]. Subsequent
study from Yan et al. showed long-term colonization of 2 month old GF mice with conventional specific
pathogen-free GM for 8 months results in equalization of bone mass between GF and conventional
groups. Long term conventionalization of GF mice also increased longitudinal and radial bone growth,
although an acutely reduced bone mass was found when a short-term (1 months) colonization was
conducted [90]. Colonized GF mice also showed an increased circulating level of insulin-like growth
factor 1 (IGF-1), a hormone known to effectively regulate skeletal growth. Together, these observations
suggest a complex relationship between GM and bone remodeling over the lifetime of the animal.
Hence, the role of GM and their impact on the skeletal system requires further work developing
clinically-relevant strict GF animal quality control procedures to tease apart these effects.
3.2.2. Antibiotics Treatment Models
An alternate method to study GM is by using antibiotic treatment to kill specific subsets of bacteria.
This method has the benefit of being highly translational in order to study the impact of antibiotics in
humans as well. Treatment with broad-spectrum antibiotics commonly reduce or deplete microbiome
population in gut, with increased size of cecum, decreased proliferative cells in small intestine and
colon, but with fewer effect on overall colon length [132]. Yan et al. showed antibiotic treatment of
CONV-R mice decreases serum IGF-1 level and inhibits bone formation [90]. However, supplemental
treatment with short-chain fatty acid (SCFAs), one of the products of microbiota metabolism, restored
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serum IGF-1 and bone mass level in antibiotic-treated CONV-R mice [90], suggesting that metabolic
products of bacteria can regulate the host skeleton. The other alternative study showed a mild range
of antibiotic treatment at early life significantly increase BMD in CONV-R mice [135], as well as
serum glucose-dependent insulinotropic polypeptide (GIP), an incretin hormone promoting bone
formation [136]. Those results are consistent with the finding that daily injection of GIP could rescue
bone loss found in OVX animal model [137]. Importantly, multiple studies provide evidence that
supplementation of probiotics (i.e., Lactobacillus reuteri, Lactobacillus rhamnosus GG (LGG), Lactobacillus
paracasei and/or Lactobacillus plantarum) in OVX mice can limit bone loss by dampening osteoclastogenic
cytokine production in bone marrow and/or intestine due to ovary malfunction [138–140]. Based
on experimental data, intestinal microbiota display a great potency to regulate bone metabolism via
regulating host metabolism, immune response, and endocrine factors. Normalization of the intestinal
microbiota directly or indirectly, for example, dietary interventions by using pro-and/or synbiotics,
may be provided for pre-clinical application for treating metabolic disease and GI disorder-associated
bone disease.
3.3. Chemical Irritant-Induced Model
The use of chemical irritants to induce IBD in mice has been one of the most highly utilized,
non-genetic models for studying the impact of IBD systemically. Several such models have been
developed, and although they do not mimic the direct pathophysiology of human IBD, they display
similar phenotypic changes as human patients [141].
3.3.1. Trinitrobenzene Sulfonic Acid (TNBS)
Colitis induced by trinitrobenzene sulfonic acid (TNBS), a classical haptenating agent, is mainly
conducted through intrarectal administration to trigger production of immunogenic proteins in the
colon, thereby initiating a mucosal immune response such as increased cytokine production [142].
An early report by using TNBS-administration in rats showed that significant cancellous bone loss
(33%) could be observed 3 weeks after treatment, due to reduced cancellous bone formation rate
(<30% versus control). Following the resolution of the inflammatory process, TNBS-treated animals
exhibit increased bone formation by 12 weeks into the experiments [143], indicating the potential for
rescue after disease resolution. A recent study by Metzger et al. reported systemic inflammation
developed in TNBS-induced IBD elevates proinflammatory cytokines levels (TNF-α, IL-6, RANKL)
and decreases sclerostin, a known bone formation inhibitor, in osteocytes [91]. These findings highlight
potential contribution of bone formation modulating cells, OB, and osteocytes, in bone loss associated
with TNBS-induced IBD. Other studies demonstrated increased TNF and interferon-gamma (IFNγ) in
TNBS-treated mice can downregulate expression and activity of Klotho, an anti-inflammatory protein
by supporting renal Ca2+ homoeostasis [70,92].
3.3.2. Dextran Sulfate Sodium (DSS)
An alternate chemically induced IBD model is the well-established DSS colitis model. This model
utilizes DSS to induce dysfunction of intestinal epithelial barrier, thereby resulting in exaggerated
entry of luminal bacteria or antigen into mucosa [144,145]. The effect of DSS on the induction of
bone loss is dependent upon DSS dosage, treatment periods, and animal background (age, sex, and
species). Low dose treatment of DSS (1%) in 5–6 weeks old male mice for 15 days induced a moderate
intestinal inflammation without weight loss [95]. Those mice displayed significant trabecular bone loss
with increased TNF-α in bone and colon, which is negatively correlated with OB activity, leading to
decreased bone formation rate, but few effects on cortical bone. Interestingly, low dose DSS treatment
induces a redistribution of fat storage from subcutaneous to visceral sites, which is reported to be
more proinflammatory and consistent with disease pathologies (e.g., Creeping fat accumulation)
found in CD patients [146–148]. Studies from Harris et al. reported a transition in bone composition
occurred following active IBD phases [93]. During active disease phase, DSS-treated mice showed
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a significant decrease in tibial trabecular and cortical bone parameters, lower vertebral trabecular
bone parameters, but few effects on calvaria BMD. Active inflammation in intestine is associated
with dramatically increased serum level of TNF-α and reduced IGF-1, associated with decreased
bone length, growth plate thickness, and cartilage markers. However, both OC and OB activity
declined during active disease stage, indicating decreased overall bone remodeling. During disease
recovery, DSS-treated mice recovered body weight and skeletal response. Different from previous
groups, Hamdani et al. [149] used Balb/C mice to investigate DSS colitis-induced bone loss, and they
found reduced femoral bone mass resulting from suppressed bone formation and increased bone
resorption in the DSS-colitis model. Interestingly, endogenous bone marrow mesenchymal stem cells
(BMMSCs) have an immunosuppressive capacity, maintained by autophagy, that can improve the
intestinal pathologic index in DSS-colitis mice, highlighting reciprocal interaction between the gut
and bone [150]. However, BMMSCs from OVX mice lost this immunoregulatory capacity, exhibited
decreased osteogenic differentiation and increased adipogenic differentiation. The restoration of
autophagy by rapamycin rescued BMMSCs’ healing capacity and attenuated the OP phenotype in OVX
mice. These different findings indicate the despite its simplicity and wide application, DSS-induced
colitis is complicated by various factors, which make it challenging to study the impact of colitis
on bone. However, this can also provide insight into the various modes and severity of intestinal
inflammation-associated bone loss observed in human patients.
3.4. Immune Cell-Transfer Induced Model (CD45RB Model)
A prominent feature of chronic gut inflammation in IBD is the presence of activated inflammatory
T cells as well as their secreted cytokines. Differentiation/expansion of donor (Wild-type)-derived naïve
(CD4+CD45RBHi) T cells in immune-deficient recipient (Rag−/−; scid/scid mice) induces transmural
colitis with severe inflammation within small bowel [151]. Experimental data showed that, in addition
to colitis, scid/scid mice transferred with CD4+CD45RBHi T cells (CD45RB mice) developed osteopenia
characterized with decreased total (trabecular and cortical) BMD, increased OC number in long bone
surface and decreased number of OBs [96]. CD45RB mice also displayed bone marrow inflammatory
cells expressing higher TNF-α. Prophylactic treatment with Fc-OPG, a soluble decoy receptor binding
and neutralizing RANKL, increased bone density in CD45RB mice by preventing OC function,
normalizing serum Ca2+ and Pi concentration, but failed to recover gut inflammation. A similar
therapeutic function of OPG in gut-inflammation associated bone loss was also found in IL-2−/−
colitis mice, in which both skeletal abnormalities and colitis score were reduced by modulation of
RANKL-RANK interactions with exogenous administration of Fc-OPG [72]. The potential critical effect
of systemic and intestinal RANKL in bone loss and osteoclastogenesis is also revealed in our recent
study [80]. To sum up, the role of the RANK/RANKL signaling pathway in location inflammation is
still needed to be addressed in different gut inflammation models.
4. Networks of Gut-Residing Factors Regulating Bone Marrow Microenvironment and Bone Loss
The intestine and bone marrow are two representative central reservoirs of immune cells. Inflamed
gut environment, driven by unrestrained immune-cell activation, increased pro-inflammatory cytokine
production, associated with altered resident microbiotas and dysfunction of epithelial barrier, results
in increased inflammation in bone marrow microenvironments and subsequently decreased bone mass
(Figure 1).
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Figure 1. Networks of gut-immune response in bone loss. Many factors, including microbiota and/or
barrier-damaging factors (e.g., DSS), have been validated in triggering gut inflammation, such as
IBD. In inflamed gut, epithelial barrier function can be regulated by nuclear receptros (VDR, FXR),
inflammatory signals (NF-κB), and various stress stimulators (ROS, Endoplasmic Reticulum (ER)
stress). Various inflammatory responses can be activated in the lamina propria by the infiltrating
bacteria and/or local released inflammatory cytokines from epithelium cells. Dysregulation of the
balance between mucosal immune cells orchestrate cytokines production and releasing to blood
stream. Systemically provided inflammatory cytokines could be transmitted to bone marrow to enable
activation of osteoclastogenic immune cells and cytokines, leading to activated bone resorption process
by osteoclasts (OC).
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4.1. Intestinal Barrier-Regulated Bone Loss
Intestinal epithelial barrier, an integral component of innate immunity, provides a shield against
microorganisms harbored in lumen. The intestinal barrier is mainly composed of a single layer of
various cell types (i.e., IEC, enterocytes, goblet cells, neuroendocrine cells, tuft cells, Paneth cells, and
M cells), which respond to various extracellular stimuli and provide priming and activation signals
to a diversity of immune cells residing in the lamina propria to promote an effective inflammatory
response [152,153]. The intestinal epithelial cells make up the majority of the luminal surface where
they are connected by tight junctions (TJ), which are responsible for connecting adjacent epithelial cells
and are critical for controlling interepithelial permeability and selectively controlling passage of small
molecules. Studies in active CD patients showed increased intestinal paracellular permeability which
is associated with altered TJ protein complex, such as suppressed expression of transmembrane protein
occludins, and claudins 5 and 8, but upregulated claudin-2, a mediator of leaky gut barrier [154].
These emphasize the key role of TJ protein in shaping epithelial structure, restraining pathogen passage,
and maintaining gut barrier function.
Current knowledge of the crosstalk between intestine and bone during gut inflammation is based
off both clinical and animal models [155]. Pediatric IBD patients showed an increased likelihood to
develop OP or osteopenia due to impaired barrier function. Early studies showed that premature
birth can increase intestinal permeability and, surprisingly, bone mineral content [156]. Another study
found that infants with low birth weight were more likely to develop bone metabolic disease [157].
The effects of intestinal health during early development can clearly have long-term effects on bone
health, especially since younger children undergo higher rates of bone remodeling. This could also be
potentially associated with high permeability of intestinal barrier during early phase of development.
Breastfeeding may allow passage of multiple components, including lactoferrin, transforming growth
factor beta (TGFβ), and epidermal growth factor (EGF) from the mother’s colostrum to the infants’ blood.
Those components improve infants’ intestinal permeability by promoting TJ protein expression [158],
as well as provide easily digestible nutrition for infants. In addition, IgA antibodies found in breast
milk have been shown to improve gut microbiota and overall intestinal health, reducing the risk of
IBD. Although more evidence is needed to prove an association between bone loss and intestinal
barrier dysfunction, studies on animal models using chemically-induced barrier permeability [93,149]
and by targeting epithelial function through genetic modification [80], support this notion. A major
drawback of this clinical finding is small sample sizes and highly specific patient populations that may
not represent broad patient groups. Typically, proinflammatory cytokines TNFα and IL-1β, which
are increased in IBD patients, have been shown to directly increase IEC permeability by interrupting
TJ proteins, associated with increased activation of NF-κB signaling, the primary inflammatory
response pathway [159–162]. Those results are consistent with our findings in IKK2caIEC mice,
wherein constitutive activation of NF-κB signaling pathway in IECs [80], which mimics chronic
inflammation, can induce gut damage and directly affect bone regulating cells (such as OC precursors)
via gut-secreted cytokines.
A recent update shows that intestinal epithelial barrier can respond to endoplasmic reticulum
(ER) stress under inflammatory conditions, and Genome-wide association studies, (GWAS) based on a
large cohorts of IBD patients undercovering over 300 susceptibility genes, revealed a high correlation
between endoplasmic reticulum stress as well as unfolded proteins (UPR)-related genes and the
pathogenesis of IBD [163,164]. Reports on animal studies showed that mice with epithelial-specific
deletion of X-box-binding protein (XBP1) spontaneously developed enteritis, exhibited a higher
susceptibility to induce colitis due to dysfunction of Paneth cells and high sensitivity to bacterial
products (flagellin) and TNFα [165]. Another recent study emphasizing the importance of ER
protein in epithelial function displayed mice with epithelial specific disruption of Inositol Requiring
Enzyme1α, an ER transmembrane protein serving as the major sensor under stress, spontaneously
developed colitis with a loss of goblet cells and failure of intestinal epithelial barrier function [166].
The importance of ER stress signaling is not only reflected by its role in maintaining physiology,
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but also by its high response to genetic mutations, oxidative stress, process of aging, and/or various
environmental factors that can lead to different diseases such as obesity, inflammation, diabetes, GI
disorders, and rheumatic disease (RA) [167–169]. In spite of the lack of evidence proving direct link
between ER stress presented in IBD and bone disease, the promising effect of UPR in bone cells
differentiation and functions has been investigated in multiple studies. Scheiber et al. showed that
G610C osteogenesis imperfecta mice had longitudinal bone growth retardation, characterized by
accumulated hypertrophic chondrocytes expressing ER dilation, and mutated type I collagen which
induce osteoblast dysfunction due to ER stress [170]. ER stress also reflects one of the promising
therapeutic mechanisms during rheumatoid disease process. For example, induction of UPR signaling
by inflammatory cytokines and autoantibodies can act as upstream pathway to induce inflammatory
responses during RA pathogenesis [169]. Upregulated expression of representative ER stress markers,
including GRP78, IRE1, XBP1s, ATF6, and eIF2α-P, were found in macrophages and synovial tissues
from RA patients [171,172]. Tauroursodeoxycholic acid (TUDCA), an endogenous chemical chaperone
that protects cells against ER stress, has been shown to attenuate intestinal inflammation and barrier
disruption in various disease models, such as DSS-induced colitis [173,174] and non-alcoholic fatty
liver disease [175]. The effect of TUDCA in bone was also investigated in experimental models
which displayed that TUDCA was comparable to recombinant human bone morphogenetic protein-2
possessing osteogenic potential in a mouse spinal injury model [176], and an alternative treatment
to restore OA cartilage by balancing intracellular cholesterol levels in chondrocytes [177]. Therefore,
targeting dysregulated UPR signaling in gut and/or bone marrow microenvironment may be proposed
as new therapeutic strategy for IBD-associated bone destruction.
Another recent potential theory that links intestinal barrier dysfunction and skeletal failure
presented in IBD could be autophagy, a conserved catabolic process by which cells control degrading
damaged protein, dysfunctional organelles and clearance of bacteria [178]. Activation of autophagy
machinery has been indicated in various human diseases [179]. GWAS analysis identified autophagy
protein (ATG16L1) as an IBD susceptibility gene [180], representing key roles in both human and mouse
intestinal Paneth cells [181]. Adolph et al. reported that mice with epithelial specific compromised
UPR (XBP1) and autophagy function (ATG16L1) spontaneously developed severe CD-like transmural
ileitis [182], accompanied with NF-κB overactivation-mediated intestinal inflammation. Several
studies revealed regulation of autophagy on bone cell development and function, as well as the
effects of autophagy on bone microenvironment are context-dependent [183–187]. Wu et al. reported
that IEC-specific VDR regulated ATG16L1 level at both transcriptional and translational level [188].
Additionally, the negative correlation of intestinal VDR expression and ATG16L1 is found in UC
patients as well as IL-10−/−mice with colitis. Bone marrow-derived macrophages from IL-10−/−mice
displayed an impaired induction of autophagic pathway upon LPS stimulation [189], implicating
selective local activation of autophagy, i.e., in gut or bone, may explain osteopenia shown in IL-10−/−
mice [68]. Qi et al. presented that autophagy maintains the immunoregulatory capacities of BMMSCs
in modulating T cells apoptosis, gut inflammation in DSS-colitis mice, but BMMSCs from OVX/OP
models failed to exert regeneration capacity [150]. Clinical data also showed promising therapeutic
effect of mesenchymal stem cells for the treatment of UC [190]. Overall, these findings indicate that
modulation of novel signaling pathways, such as NF-κB, UPR, and autophagy, can regulate cytokine
production in the inflamed gut environment to limit bone destruction.
4.2. Effect of Gut-Derived Cytokines on Bone Marrow Microenvironment
Patients with IBD display elevated levels of circulating pro-inflammatory cytokines with
osteoclastogenic function, such as TNFα, IL-1β, IL-6, IL-11, IL-17, and prostaglandin E2 [7]. These
osteoclastogenic factors presumably act on OC precursors residing in bone microenvironment to
promote OC differentiation and bone resorbing capacity. Additionally, some of those cytokines
disrupt bone formation by inhibiting OB differentiation and bone formation. Thus, the dual effects of
these inflammatory cytokines lead to a substantial bone erosion effect and further result in skeletal
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anomaly. Neutralization of pro-inflammatory cytokines, such as TNFα and IL-6, which are increased
in the circulation of active IBD patients, can therapeutically recover IBD-associated bone loss [191],
highlighting the important role of effector cytokines in the effects of IBD on bone remodeling. In murine
studies, varying contributions of cytokines in IBD-associated bone defects have been reported.
At the onset of IBD, dysfunction of epithelial barrier with higher permeability cause accumulation
of GM and increased innate immune cells response, excessive influx and activation of lymphocytes
including neutrophils, macrophages, dendritic cells, and innate lymphoid cells (ILC) [192]. These cells
produce high quantities of pro-inflammatory cytokines (IL-1β and TNFα), which are more actively
produced at the onset of gut inflammation [193,194]. Our most recent studies showed both IEC and
ILCs, the representative innate immunity regulating components, are responsible for initiation of
murine osteopenia due to intestinal barrier dysfunction [80]. Furthermore, since IBD is characterized
by recurrent chronic inflammation, the adaptive immune response plays a key role in the development
of IBD-associated bone loss [195]. Gut inflammation has been characterized by overactivated
pro-inflammatory cytokine-producing T-helper cells, such as Th1 and Th17, in addition to ineffective
anti-inflammatory regulatory T cells to resolve the inflammation [195]. Unrestrained gut-immunity
in IBD is associated with divergent responses in lymphoid and myeloid hematopoiesis in the bone
marrow. Trottier et al. and others showed that colitis in mice induces significant increase of neutrophils,
monocytes, and granulocytic lineage, but a decline of lymphocyte population (B and T cell lineage)
in bone marrow and peripheral blood, which is consistent with the highly infiltrated monocytes and
neutrophils in intestine [196,197]. However, the key drivers of inflammation in the IBD-derived bone
marrow still remain to be addressed. Ciucci et al. identified in two characterized mouse models of IBD
(IL-10−/− and CD45RB model), as well as CD patients, that bone marrow-Th17 cells expressed higher
levels of osteoclatogenic cytokines, including IL-17 and TNFα upon gut inflammation [69]. These
findings are consistent with previous observations that intestinal inflammation in IL-2−/− mice is
associated with activated T cells accumulation in the bone marrow and highly produced RANKL [72].
Oostlander et al. also suggested an important role of IL-17 in OC differentiation in CD patients [198].
Attenuation of NF-κB signaling during gut inflammation in mice limit bone loss by modulating
circulating IL-17 level [80], highlighting the key function of IL-17 in gut-bone inflammation.
To date, direct evidence supporting the effect of gut-residing cells as well as their secreted
cytokines on bone remodeling still needs further exploration. However, gut microbial dysbiosis may
be the key driver to aberrant immune response, often accompanied with imbalanced production
of inflammatory cytokines. Data of the Human Functional Genomics Project, derived from in vitro
stimulation experiments, demonstrate that TNFα and IFNγ production are more directly influenced
by the GM [199], suggesting the possibility of modulating the host immune response by manipulating
microbiota-mediated factors, i.e., cytokines, rather than direct targeting of the immune cells. Mice in GF
condition exhibit increased bone mass and compromised marrow CD4+ T cells and osteoclastogenic
cytokines, which can be normalized by conventionalization [88,89,139,200]. Shaping of GM in B27-tg
rats modulates onset of gut and joint inflammation [104]. Several experimental studies also emphasize
the critical role of microbial dysbiosis in linking metabolic dysfunction-associated gut inflammation
and bone loss [201]. For example, mice with ovary dysfunction display an increased intestinal
permeability [139,202] with altered intestinal TJ and cytokine gene expression [202]. Probiotics
supplementation improves bone loss and intestinal permeability following OVX [138–140]. GF mice
are protected from bone loss and barrier dysfunction due to sex-steroid deprivation, by dampening
bone marrow and gut-derived proinflammatory cytokines [139]. Therefore, inflammatory cytokines
and GM can be seen as the key drivers regulating inflamed gut and it manifested bone disorder, which
can be a potential clinical frontier to limit skeletal disease activity.
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5. Closing Remarks
During the past decade, plenty of research has focused on the skeletal abnormalities seen in
IBD patients or animal models. Many risk factors including genetics and environmental elements
are suggested to be associated with reduced bone mass in IBD patients. The various pathological
mechanisms by which gut inflammation can exacerbate deterioration bone architectures are still under
on-going debate. Development of a specific therapeutic strategy coping with a number of cohort
effects (age, district, genetic background, disease activity, etc.) need to be considered by physicians
and researchers [203,204]. Progress on experimental studies of animal models implicates dysbiosis of
the intestinal microbiota, and its related inflammatory cytokines, is the key player driving systemic
inflammation and subsequently resulting in bone loss. However, the understanding of pathogenic
mechanisms defining interactions between bone and intestine is still at an early stage. More clinical and
preclinical studies with well-designed human and animal models of IBD need to focus on interrogating
major inflammatory mediators and key players that can influence gut-bone axis signaling in order to
reduce the morbidity associated with gut-disease mediated bone loss.
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